FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

6 results

adcirca
(Tadalafil)
United Therapeutics Corporation
Usage: ADCIRCA® is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability, specifically in patients with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH associated with connective tissue diseases.
orenitram
(treprostinil)
United Therapeutics Corporation
Usage: Orenitram is indicated for treating pulmonary arterial hypertension (PAH) to delay disease progression and improve exercise capacity, primarily in patients with WHO functional class II-III symptoms, including idiopathic, heritable, or connective tissue disease-associated PAH.
remodulin
(treprostinil)
United Therapeutics Corporation
Usage: Remodulin is used to treat pulmonary arterial hypertension (PAH) to alleviate symptoms during exercise in patients with NYHA Functional Class II-IV. It is also indicated for those transitioning from epoprostenol to reduce clinical deterioration. Indications include idiopathic, heritable PAH, congenital shunts, and connective tissue diseases.
tyvaso
(treprostinil)
United Therapeutics Corporation
Usage: Tyvaso is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability in patients, especially those with NYHA Functional Class III symptoms. It is also approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD), enhancing exercise capacity in affected patients.
tyvaso dpi
(treprostinil)
United Therapeutics Corporation
Usage: Tyvaso DPI is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in patients, particularly those with NYHA Functional Class III symptoms. It is also indicated for pulmonary hypertension associated with interstitial lung disease (PH-ILD) to enhance exercise capacity.
unituxin
(DINUTUXIMAB)
United Therapeutics Corporation
Usage: Unituxin (dinutuximab) is indicated for pediatric patients with high-risk neuroblastoma who show at least a partial response to prior multiagent therapy. It is used in combination with GM-CSF, IL-2, and 13-cis-retinoic acid for treatment.

United Therapeutics Corporation drugs

adcirca

orenitram

remodulin

tyvaso

tyvaso dpi

unituxin